Fig. 4: evACE2 inhibits SARS-COV-2 infection and inflammation in hACE2 transgenic mice.
From: Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
a Probability of severe disease-free survival in B6.Cg-Tg(K18-ACE2)2Prlmn/J (K18-hACE2) mice receiving SARS-CoV-2 infection (10,000 pfu) and intranasal EVs (130 µg as measured on Nanodrop) per mouse (evCon in light blue and evACE2 in green). Log-rank (Mantel–Cox) and Gehan–Breslow–Wilcoxon tests ****p = 2.27E−07. b Viral loads in mouse lungs on day 5/6 after receiving SARS-CoV-2 infection and administration of evCon (N = 5 mice) (light blue) or evACE2 (N = 10 mice) (green). T-test–nonparametric-one tailed, *p = 0.013. Data are presented as mean values ± SD. c. Representative H&E images of mouse lung sections at day 5 or 6 post virus inoculation and EV treatment (evCon and evACE2) intranasally. d, e Acute and chronic inflammation scores (d), and alveolar hemorrhage and necrosis scores (e) in mouse lungs on day 5/6 after receiving evCon (N = 5 mice) (light blue) or evACE2 (N = 7 mice) (green). T-test–nonparametric-one tailed, **p = 0.005, **p = 0.003 and ***p = 0.0004. Data are presented as mean values ± SD.
